Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in children in the United States

References

• Centers for Disease Control and Prevention [Internet]. The Pink Book: epidemiology and prevention of vaccine-preventable diseases. Chapter 17: pneumococcal disease. Atlanta (GA): CDC; 2018 [2019 September 18]. Available from: https://www.cdc.gov/vaccines/pubs/pinkbook/pneumo.html
   Google Scholar
• Centers for Disease Control and Prevention [Internet]. Active bacterial core surveillance (ABCs) report: Streptococcus pneumoniae. Atlanta (GA): CDC; 2017 [2020 April 15]. Available from: https://www.cdc.gov/abcs/reports-findings/survreports/spneu17.html
   Google Scholar
• Stockmann C, Ampofo K, Byington CL, et al. Pneumococcal meningitis in children: epidemiology, serotypes, and outcomes from 1997-2010 in Utah. Pediatrics. 2013;132(3):421–428.
   PubMed Web of Science ®Google Scholar
• Said MA, Johnson HL, Nonyane BA, et al. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS One. 2013;8(4):e60273.
   PubMed Web of Science ®Google Scholar
• Huang SS, Johnson KM, Ray GT, et al. Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine. 2011;29(18):3398–3412.
   PubMed Web of Science ®Google Scholar
• Wahl B, O’Brien KL, Greenbaum A, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15. Lancet Glob Health. 2018;6(7):e744–e757.
   PubMed Web of Science ®Google Scholar
• Suaya JA, Gessner BD, Fung S, et al. Acute otitis media, antimicrobial prescriptions, and medical expenses among children in the United States during 2011-2016. Vaccine. 2018;36(49):7479–7486.
   PubMed Web of Science ®Google Scholar
• Tong S, Amand C, Kieffer A, et al. Trends in healthcare utilization and costs associated with acute otitis media in the United States during 2008-2014. BMC Health Serv Res. 2018;18(1):318.
   PubMed Web of Science ®Google Scholar
• Vergison A, Dagan R, Arguedas A, et al. Otitis media and its consequences: beyond the earache. Lancet Infect Dis. 2010;10(3):195–203.
   PubMed Web of Science ®Google Scholar
• Advisory Committee on Immunization Practices. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000;49:1–35.
   Google Scholar
• Centers for Disease Control and Prevention [Internet]. Pneumococcal disease: surveillance and reporting. Atlanta (GA): CDC; 2017 [2019 September 18]. Available from: https://www.cdc.gov/pneumococcal/surveillance.html
   Google Scholar
• Kawai K, Adil EA, Barrett D, et al. Ambulatory visits for otitis media before and after the introduction of pneumococcal conjugate vaccination. J Pediatr. 2018;201:122–127.
   PubMed Web of Science ®Google Scholar
• Feikin DR, Kagucia EW, Loo JD, et al. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med. 2013;10(9):e1001517.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children – Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep. 2010;59:258–261.
   PubMedGoogle Scholar
• Balsells E, Guillot L, Nair H, et al. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: a systematic review and meta-analysis. PLoS One. 2017;12(5):e0177113.
   PubMed Web of Science ®Google Scholar
• Pichichero M, Kaur R, Scott DA, et al. Effectiveness of 13-valent pneumococcal conjugate vaccination for protection against acute otitis media caused by Streptococcus pneumoniae in healthy young children: a prospective observational study. Lancet Child Adolesc Health. 2018;2(8):561–568.
   PubMedGoogle Scholar
• Beall B, Chochua S, Gertz RE, Jr., et al. A population-based descriptive atlas of invasive pneumococcal strains recovered within the U.S. during 2015-2016. Front Microbiol. 2018;9:2670.
   PubMed Web of Science ®Google Scholar
• Kandasamy R, Voysey M, Collins S, et al. Persistent circulation of vaccine serotypes and serotype replacement after 5 years of infant immunization with 13-valent pneumococcal conjugate vaccine in the United Kingdom. J Infect Dis. 2020;221:1361–1370.
   PubMed Web of Science ®Google Scholar
• Rupp R, Hurley D, Grayson S, et al. A dose ranging study of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants. Hum Vaccin Immunother. 2019;15(3):549–559.
   PubMed Web of Science ®Google Scholar
• Greenberg D, Hoover PA, Vesikari T, et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants. Vaccine. 2018;36(45):6883–6891.
   PubMed Web of Science ®Google Scholar
• Varghese J, Chochua S, Tran T, et al. Multistate population and whole genome sequence-based strain surveillance of invasive pneumococci recovered in the USA during 2017. Clin Microbiol Infect. 2020;26:512.e511.
   Web of Science ®Google Scholar
• Balsells E, Dagan R, Yildirim I, et al. The relative invasive disease potential of Streptococcus pneumoniae among children after PCV introduction: a systematic review and meta-analysis. J Infect. 2018;77(5):368–378.
   PubMed Web of Science ®Google Scholar
• Adam HJ, Golden AR, Karlowsky JA, et al. Analysis of multidrug resistance in the predominant Streptococcus pneumoniae serotypes in Canada: the SAVE study, 2011-15. J Antimicrob Chemother. 2018;73(7):vii12–vii19.
   PubMedGoogle Scholar
• Martin JA, Hamilton BE, Osterman MJK, et al. Births: final data for 2018. Natl Vital Stat Rep. 2019;68(13):1–47.
   Google Scholar
• Centers for Disease Control and Prevention [Internet]. Active bacterial core surveillance (ABCs): surveillance report. Atlanta (GA): CDC; 1999 [updated 1999]. Available from: https://www.cdc.gov/abcs/reports-findings/survreports/spneu99.html
   Google Scholar
• Centers For Disease Control and Prevention [Internet]. Active bacterial surveillance (ABCs): surveillance report. Atlanta (GA): CDC; 2009. Available from: https://www.cdc.gov/abcs/reports-findings/survreports/spneu09.html
   Google Scholar
• Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32–41.
   PubMed Web of Science ®Google Scholar
• Moore MR, Link-Gelles R, Schaffner W, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15(3):301–309.
   PubMed Web of Science ®Google Scholar
• Olarte L, Barson WJ, Barson RM, et al. Impact of the 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis in US children. Clin Infect Dis. 2015;61(5):767–775.
   PubMed Web of Science ®Google Scholar
• McEllistrem MC, Adams JM, Patel K, et al. Acute otitis media due to penicillin-nonsusceptible Streptococcus pneumoniae before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis. 2005;40(12):1738–1744.
   PubMed Web of Science ®Google Scholar
• Kaur R, Morris M, Pichichero ME. Epidemiology of acute otitis media in the postpneumococcal conjugate vaccine era. Pediatrics. 2017;140(3):e20170181.
   PubMed Web of Science ®Google Scholar
• Rubin JL, McGarry LJ, Strutton DR, et al. Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine. 2010;28(48):7634–7643.
   PubMed Web of Science ®Google Scholar
• Nyman JA. Cost recommendations in the second edition of cost-effectiveness in health and medicine: a review. MDM Policy Pract. 2018;3(1):2381468318765162.
   Google Scholar
• United States Department of Labor [Internet]. Bureau of labor statistics: databases, tables & calculators by subject. Washington (DC): US Dept. of Labor; 2017 [cited 2018 July 06]. Available from: https://data.bls.gov/timeseries/CUUR0000SAM?output_view=pct_12mths
   Google Scholar
• Myers AL, Hall M, Williams DJ, et al. Prevalence of bacteremia in hospitalized pediatric patients with community-acquired pneumonia. Pediatr Infect Dis J. 2013;32(7):736–740.
   PubMed Web of Science ®Google Scholar
• Dasbach EJ, Elbasha EH. Verification of decision-analytic models for health economic evaluations: an overview. Pharmacoeconomics. 2017;35(7):673–683.
   PubMed Web of Science ®Google Scholar
• Johnson HL, Deloria-Knoll M, Levine OS, et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med. 2010;7(10):e1000348.
   PubMed Web of Science ®Google Scholar
• Joloba ML, Windau A, Bajaksouzian S, et al. Pneumococcal conjugate vaccine serotypes of Streptococcus pneumoniae isolates and the antimicrobial susceptibility of such isolates in children with otitis media. Clin Infect Dis. 2001;33(9):1489–1494.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention [Internet]. Active bacterial core surveillance (ABCs): surveillance reports. Atlanta (GA): CDC; 2019 [2019 September 18]. Available from: https://www.cdc.gov/abcs/index.html
   Google Scholar
• Moore MR, Gertz RE, Jr., Woodbury RL, et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis. 2008;197(7):1016–1027.
   PubMed Web of Science ®Google Scholar
• Hicks LA, Harrison LH, Flannery B, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis. 2007;196(9):1346–1354.
   PubMed Web of Science ®Google Scholar
• Kaplan SL, Barson WJ, Lin PL, et al. Serotype 19A Is the most common serotype causing invasive pneumococcal infections in children. Pediatrics. 2010;125(3):429–436.
   PubMed Web of Science ®Google Scholar
• Klugman KP. Herd protection induced by pneumococcal conjugate vaccine. Lancet Glob Health. 2014;2(7):e365–e366.
   PubMed Web of Science ®Google Scholar
• Hammitt LL, Akech DO, Morpeth SC, et al. Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus influenzae in Kilifi, Kenya: findings from cross-sectional carriage studies. Lancet Glob Health. 2014;2(7):e397–e405.
   PubMed Web of Science ®Google Scholar
• van der Linden M, Falkenhorst G, Perniciaro S, et al. Effectiveness of pneumococcal conjugate vaccines (PCV7 and PCV13) against invasive pneumococcal disease among children under two years of age in Germany. PLoS One. 2016;11(8):e0161257.
   PubMed Web of Science ®Google Scholar
• Andrews N, Kent A, Amin-Chowdhury Z, et al. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: the indirect cohort design, 2006-2018. Vaccine. 2019;37(32):4491–4498.
   PubMed Web of Science ®Google Scholar
• Delgleize E, Leeuwenkamp O, Theodorou E, et al. Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model. BMJ Open. 2016;6(11):e010776.
   PubMed Web of Science ®Google Scholar